本帖最后由 老马 于 2013-3-13 13:43 编辑 + _: d, F8 L" @8 {2 t7 T* x1 j
0 r( D3 I$ g7 \: d
健择（吉西他滨）+顺铂+阿瓦斯汀
7 }1 m* c0 ^% k Gemzar +Cisplatin + Avastin) W% C. p3 [' t) J$ Y
http://annonc.oxfordjournals.org/content/21/9/1804.full
0 ~4 C; W+ V" R' \1 Q' U9 N+ pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 S# i4 z0 N+ J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' ]4 N4 Z4 N! u3 t B4 J0 p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% k' \- E; Y7 [% ]4 Y T; l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
# P# R! N+ ~! K" ^+ z" l
华为网盘附件：5 W% H( ?; O( s9 ^* g8 G
【华为网盘】ava.JPG: c; P' ?! M M. z; i
|
11011102001537 )
显身卡
